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Background: Interleukin-7 (IL-7) acts primarily on T cells to promote their differentiation, survival, and homeostasis.
Under disease conditions, IL-7 mediates inflammation through several mechanisms and cell types. In humans, IL-7
and its receptor (IL-7R) are increased in diseases characterized by inflammation such as atherosclerosis, rheumatoid
arthritis, psoriasis, multiple sclerosis, and inflammatory bowel disease. In mice, overexpression of IL-7 results in
chronic colitis, and T-cell adoptive transfer studies suggest that memory T cells expressing high amounts of IL-7R
drive colitis and are maintained and expanded with IL-7. The studies presented here were undertaken to better
understand the contribution of IL-7R in inflammatory bowel disease in which colitis was induced with a bacterial
trigger rather than with adoptive transfer.
Methods: We examined the contribution of IL-7R on inflammation and disease development in two models of
experimental colitis: Helicobacter bilis (Hb)-induced colitis in immune-sufficient Mdr1a−/− mice and in T- and
B-cell-deficient Rag2−/− mice. We used pharmacological blockade of IL-7R to understand the mechanisms involved
in IL-7R-mediated inflammatory bowel disease by analyzing immune cell profiles, circulating and colon proteins,
and colon gene expression.
Results: Treatment of mice with an anti-IL-7R antibody was effective in reducing colitis in Hb-infected Mdr1a−/−
mice by reducing T-cell numbers as well as T-cell function. Down regulation of the innate immune response was
also detected in Hb-infected Mdr1a−/− mice treated with an anti-IL-7R antibody. In Rag2−/− mice where colitis was
triggered by Hb-infection, treatment with an anti-IL-7R antibody controlled innate inflammatory responses by
reducing macrophage and dendritic cell numbers and their activity.
Conclusions: Results from our studies showed that inhibition of IL-7R successfully ameliorated inflammation and
disease development in Hb-infected mice by controlling the expansion of multiple leukocyte populations, as well as
the activity of these immune cells. Our findings demonstrate an important function of IL-7R-driven immunity in
experimental colitis and indicate that the therapeutic efficacy of IL-7R blockade involves affecting both adaptive
and innate immunity.
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Inflammatory bowel disease (IBD) is characterized by
chronic and relapsing inflammation of the gastrointes-
tinal tract. In humans, Crohn’s disease and ulcerative
colitis are driven by a complex interplay between genetic
and environmental factors, which contribute to chronic
inflammation. Mouse models of colitis have been useful
in determining the contributions of specific adaptive and
innate immune mechanisms involved in the pathogen-
esis of IBD [1]. Experimental studies in mice have
revealed that a combination of genetic factors, diet, and
immune responses to microbial organisms can contrib-
ute to IBD susceptibility.
In both humans and mouse models, several lines of
evidence suggest a significant role for IL-7 in inflamma-
tory diseases, including IBD. Firstly, under normal con-
ditions, local IL-7 production acts on resident T cells
through IL-7 receptor (IL-7R; a heterodimer composed
of IL-7Rα and IL-2Rγ chains) to promote their differen-
tiation, survival and homeostasis [2]. IL-7 is produced by
stromal cells and intestinal epithelial cells, suggesting a
role for IL-7 in modulating immune responses in the in-
testinal microenvironment. Secondly, elevated serum
concentrations of IL-7 have been detected in patients
with ulcerative colitis [3] and Crohn’s disease [4], and
gastric tissue biopsies from patients infected with H. pyl-
ori have increased IL-7 message [5]. Polymorphisms in
IL-7RA are also associated with several inflammatory
diseases including ulcerative colitis [6]. Thirdly, the im-
portance of IL-7 as a mediator of intestinal inflammation
has been demonstrated in IL-7 transgenic mice which
develop colitis resembling ulcerative colitis [7], and in
IL-7 deficient mice, which are resistant to the develop-
ment of non-T-, non-B-cell-mediated colitis [8]. Finally,
the importance of IL-7-responsive-T cells in colitis has
been demonstrated in TCRα−/− mice, which develop
spontaneous colitis driven by IL-7Rhigh memory T cells
[9,10]. Adoptive transfer studies in these mice suggest
that the colitogenic T cells are primarily memory CD4+
cells which express high IL-7Rα and are maintained and
expanded with IL-7 [9,10], indicating that IL-7 signaling
is important in IBD pathogenesis. In an adoptive T-cell-
transfer model of colitis, Yamazaki and colleagues
successfully treated ongoing colitis using a saporin-
conjugated anti-IL-7Rα antibody, selectively eliminating
lamina propria lymphocytes (LPL) with high expression
of IL-7R [10]. These and other studies suggest that ther-
apies interfering with IL-7R signaling could abrogate in-
testinal inflammation in IBD.
The aim of this study was to determine whether inhib-
ition of IL-7Rα signaling would ameliorate colon inflam-
mation induced by a bacterial trigger rather than with
adoptive transfer of T cells. We used Helicobacter bilis
(Hb) infection to induce colitis in T-cell-sufficient(multiple drug resistance 1a null; Mdr1a−/−) mice, and
T- and B-cell-deficient (recombination activating gene 2;
Rag2−/−) mice. This method has the advantage of not re-
quiring adoptive transfer of T cells into immunodeficient
hosts, which requires IL-7 for T-cell expansion and sur-
vival. In addition, our colitis models provided the oppor-
tunity to assess the cell types and functions affected by
blocking IL-7Rα in mice where intestinal immuno-
pathology is associated with T cells (in Mdr1a−/− mice),
and innate immune cells (in Rag2−/− mice). Our results
indicated that pharmacological inhibition of IL-7Rα
reduced inflammation and subsequent disease develop-
ment in Hb-infected mice by controlling the expansion
of multiple leukocyte populations, as well as the activity
of these immune cells. Our findings demonstrate an im-
portant function of IL-7R-driven immunity in experi-
mental colitis involving both adaptive and innate
immunity.
Methods
Mice, induction of colitis, and antibody treatments
Specific-pathogen free, 4–11 week old Mdr1a−/− mice
(FVB.129P2-Abcb1atm1Bor, Taconic Farms, Albany,
NY) [11,12]; bred in house), and Rag2−/− mice (129S6/
SvEvTac-Rag2) were verified to be free of Helicobacter
species by fecal PCR [13]. Mice were treated by intraper-
itoneal (IP) injection with anti-IL-7Rα M595 (rat IgG2b;
t1/2 = 3 days; Amgen Inc.) or isotype control M495 (rat
IgG2b; Amgen Inc.) antibodies twice weekly, one week
prior to oral gavage with Hb and continuing for the
study duration (total of 10 weeks for Mdr1a−/− mice and
12 weeks for Rag2−/− mice). Hb-infection was confirmed
by fecal PCR [13]. Mice were weighed weekly and eutha-
nized when they developed 20% body-weight loss or
signs of severe IBD, and tissue samples were taken. All
mice were used according to procedures approved by
Amgen’s and UW’s Animal Care and Use Committees.
Pathology and immunohistochemistry
Necropsy, tissue sampling, processing and histologic
examination was performed as previously described [11].
Cecum and colon IBD scores were based on severity of
mucosal epithelial changes, degree of inflammation and
extent of lesions [11]. 4 μm sections of formalin fixed,
paraffin embedded cecum and colon were stained with
biotinylated F4/80 antibody (clone CI:a3-1;AbD Serotec,
Raleigh, NC) or isotype control, followed by develop-
ment with horseradish peroxidase-labeled streptavidin
and diaminobenzidine substrate solution. F4/80+ cells
were scored based on numbers of cells with membrane
staining as follows: 0 = no staining, 1 =minimal to
few faintly positive cells, 2 = scattered single positive
cells, 3 = clusters of two or more positive cells, 4 = larger
clusters of positive cells, multifocal to coalescing. The
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laris/serosa of both cecum and colon were scored and
summed (maximum score = 32).
Flow cytometric analysis
Single cell suspensions were made from spleen and
MLN harvested at necropsy [14]. Cellularity was deter-
mined using a hemocytometer or with an Advia 120
Hematology Analyzer (Siemens, Deerfield, IL). Cells
were blocked with anti-CD16/CD32 (BD Biosciences,
San Jose, CA) then stained with fluorescein isothiocyan-
ate-, phycoerythrin-, peridinin-chlorophyll-protein com-
plex-Cy5.5-, or allophycocyanin-labeled antibodies (BD)
to the following surface markers: anti-CD44, CD4,
CD8a, CD62L, CD127 (clone B12-1 binds a different
epitope than 5 anti-IL-7Rα M59), CD49D (clone DX5),
CD11b, and CD11c. Data were collected on BD’s FACS-
Calibur or LSRII and analyzed using FlowJo (Tree Star,
Inc, Ashland, OR).
Serum cytokines and anti-Hb antibodies
Serum obtained at necropsy was analyzed using the Ro-
dent MAP version 2.0 antigen panel (RBM, Austin, TX).
Serum Hb-specific IgG2a was determined by ELISA as
previously described [11] with the exception of using
HRP-conjugated anti-mouse IgG2a (Southern Biotech,
Birmingham, AL).
Colonic-explant culture cytokines
5 mm of proximal colon was flushed with PBS contain-
ing penicillin/streptomycin, blotted on sterile gauze and
then cultured in RPMI supplemented with 10% FCS, 1X
non-essential amino acids (Irvine Scientific, Santa Ana,
CA), 20 mM Hepes, 100 U/ml Penicillin, 100 ug/ml
Streptomycin, 50 μM 2-mercaptoethanol, 2 mM L-glu-
tamine, 1 mM sodium pyruvate at 37°C and 5% CO2 for
24 hours. Supernatants were harvested, clarified by cen-
trifugation, and analytes were detected using the LIN-
COplex Mouse Cytokine/Chemokine Panel-32 plex
(Millipore, Billerica, MA) and a Luminex 100 IS (Lumi-
nex, Austin, TX). Data were analyzed using the Data
Interpretation Application (Luminex). Values were cor-
rected for the weight of the tissue and are presented as
concentration of protein/mg tissue in the cultures.
Quantitative RT-PCR analyses
RNA was extracted from 5 mm of proximal colon
(flushed with PBS) using the RNeasy kit (Qiagen, Valencia,
CA). RNA was converted to cDNA using the High
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems, Foster City, CA). Gene expression (relative to
HPRT) was determined using TaqManW Mouse Immune
Array (Applied Biosystems). Duplicate 150 μg cDNA
samples were loaded per reservoir. Data were collectedon an ABI 7900 LDA and analyzed using SDS v2.2.2,
Spotfire DecisionSite v19.3.1006 (TIBCO Software
Inc., Somerville, MA), Microsoft Excel 2003, and
GraphPad Prism 5. IL-7Rα expression (relative to
Gapdh) was determined on an Mx3005P (Stratagene, La
Jolla, CA) using Power SYBR Green PCR Master Mix
(Applied Biosystems). Samples were run in duplicate.
Primer sequences were as follows: IL-7Rα-forward: 50-
ACAAGAACAACAATCCCACAGAG, IL-7Rα-reverse:
50-TCGCTCCAGAAGCCTTTGAAG Gapdh forward: 50-
TTCCGTGTTCCTACCCCCAATGTG, and Gapdh re-
verse: 50-TAGCCCAAGATGCCCTTCAGTG.
Statistical methods
The Analysis of Variance (ANOVA) method was used to
determine differences between treatment groups in
colon mRNA expression, colon and serum protein
panels, and FACS data. Comparisons between individual
treatment groups were then performed with multiple
comparison adjustment using either Tukey, Dunnett, or
multivariate t methods. Homogeneous variance and nor-
mality assumptions were tested using Brown-Forsythe’s
test and Shapiro-Wilk test, respectively. If either test
showed a significant result (p < 0.01), a logarithm (loga-
rithm base 2 for mRNA data) or square root transform-
ation was considered. The transformation that satisfied
both assumption tests was applied to the data. If both
transformations failed, nonparametric ANOVA was
used. The analyses were performed using SAS© 9.2 (SAS
Institute Inc., Cary, NC). Heat maps were generated
using Spotfire DecisionSite software. For IBD scores, a
similar analysis approach was applied using Graphpad
Prism 5 software. An ANOVA analysis was per-
formed. A square root transformation was applied to
correct heterogeneous variance among groups. Tukey's
multiple comparison test was applied for group
comparisons.
Results
Blockade of IL-7Rα ameliorated Hb-induced colitis in
Mdr1a−/− mice
Mdr1a−/− mice develop colitis when infected with cer-
tain enteric helicobacter species [11]. To determine the
effectiveness of blocking IL-7Rα in colitis, we adminis-
tered an anti-IL-7Rα antibody to Mdr1a−/− mice begin-
ning one week prior to infection with Hb and continuing
for the duration of the experiment. Previous studies with
anti-IL-7Rα antibodies resulted in decreased lymphocyte
numbers in naïve and diseased mice (Amgen Inc.; data
not shown). Therefore, we used two doses of anti-IL-
7Rα M595 to determine if a 10-fold lower dose would
preserve lymphocyte numbers yet still afford protection
from colitis. As shown in Figure 1A, there was signifi-
cant suppression of IBD in all mice receiving either
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Figure 1 Anti-IL-7Rα antibody treatment reduced IBD scores and histopathology of H. bilis-induced colitis in Mdr1a−/− mice. Five-week-
old male Mdr1a−/− mice were treated IP twice weekly with 500 μg or 50 μg of anti-IL-7Rα M595, or 500 μg of isotype control antibody one week
prior to oral gavage with H. bilis (Hb, 2 × 107 CFU administered once) or broth (uninfected controls) and then treated twice weekly throughout
the duration of the study for 9 weeks post-infection. (A) Histopathological IBD scores from colon. Cecum and colon IBD scores were based on
severity of mucosal epithelial changes, degree of inflammation and extent of lesions [11]. (B) Gross and representative H&E-stained histological
sections from uninfected control (isotype broth), infected control (isotype Hb) and anti-IL-7Rα M595/500 and anti-IL-7Rα M595/50-treated
Hb-infected mice. Histological images, original magnification 10X. (C) Percent change in weight is shown for mice 1 week prior to infection
through 4 weeks post infection (last time point in which all mice were alive). ANOVA with square root transformation followed by Tukey’s
post-test (a). *p < 0.05, **p < 0.001, ***p <0.0001.
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isotype Hb-infected mice (positive controls) were irregu-
larly thickened and opaque along the entire length with
no formed fecal pellets in the distal colon and showed
severe transmural lymphohistiocytic and proliferative
colitis (Figure 1B; isotype Hb). Anti-IL-7Rα-treated Hb-
infected mice were normal with well-formed fecal pellets
in the distal colon and normal diameter of the proximal
colon and were generally considered normal histologi-
cally (Figure 1B, anti-IL-7R M595/500 Hb) or had some
mild focal colitis (anti-IL-7R M595/50 Hb). Colons from
isotype-broth (negative controls) mice were normal
grossly and histologically (Figure 1B, isotype broth).
Associated with suppression of IBD, anti-IL-7Rα-treated
Hb-infected mice had an overall trend of higher percent
weight gain compared with Hb-infected isotype-treated
mice, and the weight gain was similar to uninfected
isotype-treated mice (Figure 1C). Mice were analyzed
further to determine which immune cells and inflamma-
tory mediators were altered with anti-IL-7Rα M595
treatment.Anti-IL-7Rα M595 treatment reduced CD4+ and
CD8+ T cells
We focused our analysis on T-cell subsets trafficking to
the mesenteric lymph node (MLN) as T-cell expansion is
associated with the development of colitis in Hb-infected
Mdr1a−/− mice [11]. Flow cytometric analysis (FACS)
revealed that both doses of anti-IL-7Rα M595 significantly
prevented the expansion of total MLN cellularity and total
CD4+ and CD8+ T cells compared to both the isotype-
broth and isotype-Hb-infected mice. Treatment with both
anti-IL-7Rα antibody doses further reduced MLN, CD4+,
and CD8+ cellularity below that of Hb-infected mice trea-
ted with isotype control. However, there were significantly
more cells in the anti-IL-7Rα 50 μg-treatment group com-
pared to the 500 μg-treatment group (Figure 2A-C). The
higher dose of anti-IL-7Rα M595 resulted in a larger de-
crease in CD4+ T-cell numbers (9.8-fold decrease vs.
isotype-broth group) than in CD8+ T-cell numbers (4.5-
fold decrease vs. isotype-broth group), suggesting total
CD4+ T cells had a preferential requirement for IL-7R sig-
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Figure 2 T-cell numbers were reduced in MLN in H. bilis-infected Mdr1a−/− mice treated with anti-IL-7Rα M595. Mesenteric lymph nodes
(MLN) were harvested from mice and cells were stained with antibodies to identify T-cell subsets by flow cytometry. Total lymphoid cellularity
was determined using Advia Hematology Analyzer. (A) Total cellularity, (B) number of CD4+ cells, (C) number of CD8+ cells, (D) CD4+ to CD8+
T-cell ratio, (E) naïve (CD44-CD62Lhi) to activated/memory (CD44+CD62Llow) CD4+ T-cell ratio, (F) naïve (CD44-) to activated/memory (CD44+)
CD8+ T-cell ratio. ANOVA followed by Tukey’s post-test or multivariate t method. *p < 0.05, **p < 0.001, ***p <0.0001.
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cells similar to control groups (Figure 2D). We observed
similar results for naïve to activated/memory CD4+
(Figure 2E) and CD8+ (Figure 2F) T-cell ratios with both
doses of anti-IL-7Rα M595 treatment. The lower dose of
anti-IL-7Rα M595 preserved the ratio of CD4+ naïve to
memory T cells similar to control groups. There was a
greater decrease in absolute numbers of naïve cells versus
activated/memory cells (Additional file 1: Figure S1) with
anti-IL-7Rα antibody treatment, suggesting that naïve T
cells were more sensitive to reduced IL-7R signaling than
activated/memory T cells. Our results indicate that a rela-
tively low dose of anti-IL-7Rα M595 can protect mice
from Hb-induced colitis without inducing lymphopenia to
the extent seen with the high dose of anti-IL-7Rα M595.
Associated with the alterations in T-cell numbers, we
observed a reduction in Hb-specific IgG2a antibody titers
with anti-IL-7Rα M595 treatment (Additional file 2:
Figure S2), suggesting dysregulation of T-dependent-B-cell
responses as well.
Blocking IL-7Rα reduced mediators of colonic
inflammation and revealed a role for innate immunity
To investigate how anti-IL-7Rα antibody treatment
reduced and/or prevented inflammation in Hb-infectedMdr1a-/- mice, we analyzed messenger (m) RNA and
protein expression in colon tissues. Proximal colon
mRNA expression is depicted in a heat map (Figure 3A)
comparing expression changes occurring with infection
(mean fold change of isotype Hb divided by mean fold
change of isotype broth) and expression changes when
Hb-infected mice were treated with anti-IL-7Rα M595
antibody (mean fold change of anti-IL-7R M595 divided
by mean fold change of isotype Hb). Many cytokines,
chemokines, and cell-surface markers associated with in-
flammatory responses were increased with Hb infection
and were correspondingly decreased with anti-IL-7Rα
M595 treatment (Figure 3A). Although both doses of
anti-IL-7Rα M595 clearly prevented the inflammatory
response to Hb infection, the 500 μg dose had an
overall greater effect on regulating gene expression than
the 50 μg dose. Specifically, inflammatory cytokines
IFN-γ, IL-6, IL-1α, IL-1β, IL-12p35, and IL-17, as well
as chemokines strongly induced by IFNγ, such as acti-
vated T-cell recruiter, CXCL11 and a more general
inflammatory-cell recruiter, CXCL10, followed this pat-
tern. Costimulatory molecules (CD80, CD86, CD40,
GITR, and ICOS), adhesion molecules (VCAM-1 and
P-selectin), and signaling molecules involved in cytokine
























































































































Figure 3 Messenger RNA expression in H. bilis-infected Mdr1a−/− mice were altered with anti-IL-7Rα M595 treatment. Heat maps show
hierarchical clustering of expression of colon mRNA (A) coding fold changes of the indicated comparisons. (A) RNA was extracted from 5 mm of
proximal colon from a subset of mice (for isotype Hb group, two mice with lower scores and four with higher scores were analyzed). RNA was
converted to cDNA and then analyzed using TaqManW Mouse Immune Array. (B) Expression of proximal colon CD4 mRNA (relative to HPRT)
from the immune array, and (C) proximal colon IL-7Rα mRNA (relative to GAPDH) from single-gene RT-PCR, is shown for individual mice in
each treatment group. For (A), genes were filtered to show only those that were significantly (p < 0.05) altered between isotype Hb and
isotype-broth-treatment groups. Red indicates an increase in expression and green indicates a decrease in expression. For (B) and (C),
ANOVA followed by multivariate t method. *p < 0.05, **p < 0.001, ***p < 0.0001.
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treatment in a dose-dependent manner. Genes involved
in apoptosis inhibition (Bcl2, Vegfa) and cytokine
modulation (Socs2, Ski, Smad3) were downregulated
with Hb infection and increased with anti-IL-7Rα M595
treatment. These data also indicate that colonic IL-7
and IL-15 gene expression was downregulated with
Hb infection, and upregulated with anti-IL-7Rα M595
treatment. The decrease in these two cytokines with in-
fection and increase with anti-IL-7Rα treatment may be
due to homeostatic regulation.
RNA expression of immune-cell markers was also
altered with anti-IL-7Rα treatment. Similar to changesof CD4+ T cell numbers in MLN, colonic CD4 mRNA
expression was increased in Hb-infected mice and was
decreased in Hb-infected mice treated with both doses
of anti-IL-7Rα M595 (Figure 3B). The effect was specific
to CD4 expression (presumably on CD4+ T cells) as
there were no significant differences in CD3ε or CD8α
mRNA expression in colonic tissue (data not shown).
Although not significantly increased with Hb infection,
colonic IL-7Rα mRNA expression was reduced following
anti-IL-7Rα M595 treatment. The lower dose of anti-IL-
7Rα M595 was not associated with a significant decrease
in IL-7Rα mRNA expression compared to either control,
whereas the high dose of anti-IL-7Rα M595 had 7-fold
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isotype-Hb groups (Figure 3C). Thus, not only did anti-
IL-7Rα treatment reduce cellularity in draining lymph
nodes, but blocking IL-7Rα reduced immune-cell mar-
kers and inflammatory mediators in the colon as well.
Mdr1a−/− mice were chosen to test the effects of anti-
IL-7Rα in colitis because they are a T- and B-cell suffi-
cient strain. Although many of the changes in gene ex-
pression in the colon were related to T cells, several of
the regulated genes are involved in innate immunity. For
example, genes involved in trafficking and activation of
macrophages, natural killer (NK) cells, and dendritic
cells (DC) (CCR2, CCL19/CCR7, CCL3, CCL2, Csf3),
promotion of cellular responses (CD68, TNFα, IL-10,
CCL3, GITR, IL-6, IL-1α, IL-1β, IL-12p35), and innate
responses to bacterial infection (C3, CD40, Gusb, Nos2)
were upregulated with Hb infection and downregulated
with anti-IL-7Rα M595 treatment in a dose-dependent
manner (Figure 3A).
To correlate gene expression changes in colonic tissue
with changes in secreted proteins, we analyzed serum
samples and proximal colon explant cultures by multi-
analyte profiling. Serum protein for IL-17, IL-6, CXCL10
(IP-10), and CCL2 (MCP1) had similar expression-
pattern changes to those seen in the gene array, showing
increases with Hb infection and decreases with anti-IL-
7Rα M595 treatment (Figure 4, Additional file 3: Table
S1). Additional analytes detected in the serum (but not
represented in the gene array panel) also revealed that
blocking IL-7Rα regulated innate immune responses.
These included MIP-1γ (CCL9), MDC (CCL22), MIP-3β
(CCL19), and MPO. Analysis of local production of pro-
teins in colon explants showed expression of CCL3,
CXCL10, IFN-γ, IL-17, IL-1α and IL-1β all had similar
expression patterns compared to gene expression in ad-
jacent tissue (increased expression with Hb infection and
a dose-dependent decreased expression with anti-IL-7Rα
M595 treatment) (Additional file 3: Table S1). As an ex-
ample, correlations between histopathology scores,
serum and colon protein, and colon mRNA are shown
for CXCL10 (IP-10) in Figure 5. Taken together, these
results indicate that an innate-immune signature oc-
curred both locally and systemically in Hb-infected
mice and suggested that an anti-IL-7Rα antibody could
regulate adaptive- as well as innate-immune responses
in colitis.
Blocking IL-7Rα ameliorated colitis in the absence of
T and B cells
Given our results successfully treating Hb-induced colitis
in Mdr1a−/− mice by inhibiting IL-7R signaling, we
determined whether non-lymphoid cells also respond to
anti-IL-7Rα treatment as was suggested in the mRNA
and protein analysis. Therefore, we used T- and B-celldeficient Rag2−/− mice to determine the effects of block-
ing IL-7Rα on non-lymphoid cells in Hb-induced colitis.
We tested anti-IL-7Rα M595 at two doses (250 and
50 μg) in Hb-infected-Rag2−/− mice. Both doses sup-
pressed inflammation in Hb-infected-Rag2−/− mice, and
they were not statistically different from one another
(Figure 6A). Percent weight change was examined
throughout the duration of the study. All groups of Hb-
infected mice had a slight amount of weight loss the first
week after infection which did not occur in uninfected
mice. Starting at 2 weeks after infection, all groups of
Hb-infected mice started to gain weight which continued
for the duration of the study and were not statistically
different than uninfected mice. No differences in percent
weight change were seen between Hb-infected mice and
anti-IL-7Rα-treated Hb-infected mice (Figure 6B). Rep-
resentative H&E-stained sections of proximal colon from
uninfected control mice (isotype broth), and Hb-infected
mice treated with isotype control or anti-IL-7Rα M595
are shown in Figure 6C. Hb-induced disease in Rag2−/−
mice was less severe than that in Mdr1a−/− mice and
was characterized by moderate hyperplastic and lympho-
histiocytic colitis with elongation of colonic glands and
expansion of lamina propria and submucosa with in-
flammatory cells (isotype Hb). In contrast, the colons
from anti-IL-7Rα treated Hb-infected mice had very
mild lesions.
Multiple cell subsets were altered with IL-7Rα blockade in
Rag2−/− mice
Given that disruption of IL-7R signaling causes T cells to
decline by blocking survival and proliferation signals, it
was possible that non-lymphoid cell numbers in the
Rag2−/− mice could also be affected by IL-7Rα blockade.
To determine which cell types were involved in colitic
disease in Hb-infected Rag2−/− mice and whether the
anti-IL-7Rα antibodies had any effects on particular cell
types, we used FACS to analyze splenic macrophages,
DCs, and NK cells. Total myeloid cell numbers were sig-
nificantly increased with Hb infection and significantly
decreased with both doses of anti-IL-7Rα M595
(Figure 7A). Separation of splenocytes based on cell
surface expression of CD11c and CD11b indicated 5
populations of DCs and macrophages: Plasmacytoid
DCs (pDC; CD11b-CD11clo), myeloid DCs (mDCs;
CD11bhiCD11chi), macrophage 1 (Mac1; CD11bloCD11c-),
macrophage 2 (Mac2: CD11bhi CD11clo/-) and macro-
phage 3 (Mac3; CD11bloCD11clo) (Figure 7B). We enum-
erated NK cells using surface expression of DX5. The
expression of IL-7Rα on each subtype was determined,
and numbers of total or IL-7Rα+ pDC, mDC, NK, Mac2,
and Mac3 cells were increased with Hb infection
(Figure 7C). Mac1 cell numbers were not altered signifi-











Figure 4 Serum proteins in H. bilis-infected Mdr1a−/− mice were altered with anti-IL-7Rα M595 treatment. Heat maps show hierarchical
clustering of expression of serum proteins coding fold changes of the indicated comparisons. Serum was collected at necropsy from the majority
of mice and protein expression determined using the RodentMAP version 2.0 antigen panel. Proteins were filtered to show only those that were
significantly (p < 0.05) altered between isotype Hb and isotype-broth-treatment groups. Red indicates an increase in expression and green
indicates a decrease in expression.
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Figure 5 In H. bilis-infected Mdr1a−/− mice, changes in protein and gene expression of Cxcl10 (IP-10) correlated with histopathology
scores. IBD scores are shown in the left column for the subsets of mice used in each analysis for expression of C-X-C motif chemokine
10 (CXCL10, also known as Interferon gamma-induced protein 10 (IP-10)). The middle column shows serum and colon protein concentrations and
colon mRNA levels for the mice in the left column. The graphs in the right column show the comparisons between protein/mRNA and IBD
scores (total IBD scores for serum and proximal colon IBD scores for colon explant and mRNA analysis). Mean values for each group are shown
for the left and middle columns (horizontal line) as well as statistical significance between groups (analyzed as in Figure 1; *p < 0.05, **p < 0.001,
***p <0.0001). For serum analysis, a least detectable dose was determined for each analyte, and values at or below the limit of detection were
assigned a value of one below the least detectable dose for graphing and statistical analysis.
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http://www.journal-inflammation.com/content/9/1/39antibodies either maintained cell numbers similar to unin-
fected mice or lowered cell numbers further from unin-
fected control levels (Figure 7C). Some IL-7Rα+ cell
subsets appeared to be more sensitive to anti-IL-7Rα
M595 antibody treatment than others. For example, the
decrease in cell numbers compared to the uninfected iso-
type control group was greater for IL-7Rα+ pDC than for
total pDC (13- vs. 2.2-, and 18.6- vs. 2.1-fold decrease in
M595/250 and M595/50 groups, respectively). This was
also true for NK cells where anti-IL-7Rα M595 treatment
groups had 17- and 22-fold fewer numbers (M595/250
and M595/50 groups, respectively) of IL-7Rα+ NK cellscompared to uninfected isotype controls. This was in con-
trast to total NK cells in which anti-IL-7Rα-M595-treated
groups had similar NK-cell numbers to uninfected control
mice. Unlike the results in Mdr1a−/− mice, there were no
significant differences between anti-IL-7Rα M595 doses
on IBD scores or cell numbers in these studies. In
addition, we used F4/80 immunohistochemistry to iden-
tify macrophage/DCs in proximal colon (Figure 7D).
Consistent with findings in spleen for macrophages
and DCs, F4/80+ cells in the colon were increased
with disease and treatment with anti-IL-7Rα M595
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C Anti-IL-7R (250 ug)-treatedIsotype HbIsotype broth
Figure 6 Treatment with anti-IL-7Rα repressed IBD in T and B-cell deficient Rag2−/− mice. Seven to eleven-week-old Rag2−/− mice were
treated IP twice weekly with 250 μg or 50 μg of anti-IL-7Rα M595, or 250 μg of isotype control antibody one week prior to oral gavage with
Hb (1×106 CFU administered twice, on 2 consecutive days) or broth and then treated twice weekly throughout the duration of the study for
11 weeks post-infection. (A) Histopathological IBD scores from colon. Cecum and colon IBD scores were based on severity of mucosal epithelial
changes, degree of inflammation and extent of lesions [11]. (B) Percent change in weight is shown for mice 1 week prior to infection through
10 weeks post infection. (C) Representative H&E-stained sections of proximal colon from uninfected control (isotype broth), infected control
(isotype Hb) and anti-IL-7Rα M595 treated (250 μg) Hb-infected mice. Original magnification, 20X. ANOVA followed by Tukey's post-test on square
root transformed data (a). *p < 0.05, **p < 0.001, ***p <0.0001.
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innate immune cells, including those expressing IL-7Rα,
are involved in Hb-induced colitis, and that anti-IL-7Rα
can limit their expansion and protect from development
of colitis.
Anti-IL-7Rα treatment of Hb-infected Rag2−/− mice
reduced mediators of colonic inflammation
To assess the activity of innate cells, we measured serum
proteins by multi-analyte profiling. In the absence of T
and B cells, there were fewer analytes altered with infec-
tion or with anti-IL-7Rα M595 treatment compared with
the number of changes seen in Hb-infected Mdr1a−/−
mice. However, the majority of analytes altered in these
mice were chemotactic proteins (Figure 8). Circulating
concentrations of lymphotactin, MIP-1γ, MPO, MMP9,
as well as VCAM-1, CRP, SAP, and haptoglobin were
altered with Hb-infection and reduced in Hb-infected
mice treated with anti-IL-7Rα M595. Some analytes
were not significantly increased with infection but were
significantly reduced by treatment with the anti-IL-7Rα
M595: MCP-1, MCP-3, MDC, MIP-1α, MIP3β, GCP-2,IL-18, Tissue Factor, and TPO. Thus, in line with the re-
duction in myeloid cells, innate-immune mediators were
also reduced with IL-7Rα blockade and strongly indicate
that anti-IL-7Rα treatment controls colitis by multiple
mechanisms.
Discussion
We used two mouse models of bacterial-induced colitis
to study the effects of blocking IL-7Rα on IBD: a T- and
B-cell-sufficient strain (Mdr1a−/−) and a T- and B-cell-
deficient strain (Rag2−/−). These models were used to
circumvent the confounding variable of IL-7-dependent
expansion of T cells as occurs in colitis models that rely
on adoptive transfer of T cells into a lymphopenic envir-
onment. Our results show that IL-7Rα blockade can
ameliorate bacterial-induced colitis, and that this effect
involves not only T cells but also innate immune cells
such as macrophages, DC, and NK cells. Successful
treatment of colitis with an anti-IL-7Rα antibody was
associated with decreases in T-cell and non-T-cell popu-
lations, as well as a reduction of inflammatory cyto-



















































































































































































































































































Figure 7 Splenic macrophages, DCs, and NK cells, and colon F4/80+ cells were reduced in H. bilis-infected Rag2−/− mice treated
with anti-IL-7Rα M595. Spleens were harvested from mice and cells were stained with antibodies to identify myeloid-cell subsets by flow
cytometry. (A) Absolute numbers of splenic myeloid cells were determined using Advia Hematology Analyzer. (B) Flow cytometry gating strategy
for splenic DC- and macrophage-cell populations using CD11c and CD11b staining. (C) Absolute numbers of splenic pDC, mDC, NK cells (gated
on DX5+ cells), and macrophages, along with corresponding absolute numbers of IL-7R+ pDC, mDC, NK cells, and macrophages, were derived
from flow cytometry percentages and Advia myeloid-cell counts. (D) Sections of colon and cecum were immunostained with F4/80. The F4/80
score is a ratio of the number of F4/80+ cells to total section area. ANOVA followed by Dunnett’s or non-parametric t-test for all groups vs.
isotype Hb. *p < 0.05, **p < 0.001, ***p <0.0001.
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http://www.journal-inflammation.com/content/9/1/39T-cell-mediated activities are likely key players in IBD.
However, our results differ from some reports in that we
demonstrate that IL-7R-mediated activity on non-T and
non-B cells also contributes to experimental colitis.
In TCRα−/− mice and T-cell-transfer-induced colitis,
high expression of IL-7Rα on T cells is associated with
colitis [9,10,15], and IL-7-producing bone marrow cells
may harbor colitogenic memory CD4+ T cells [16]. The
use of a toxin-conjugated anti-IL-7Rα antibody (A7R34)
by Yamazaki and colleagues suggests that selective elim-
ination of IL-7Rαhigh CD4+ LPL is required to treat col-
itis [10]. In our studies with Mdr1a−/− mice, we noted
that all T-cell subsets in draining MLN were decreasedwith anti-IL-7Rα M595 treatment, indicating that de-
creasing total T cells (which likely included CD4+IL-
7Rαhigh cells) was in large part responsible for the lack
of colitis seen in anti-IL-7Rα M595 antibody-treated
mice. We did not detect increased colonic expression of
IL-7Rα mRNA in Hb-infected Mdr1a−/− mice. The ap-
parent discrepancy between our results of reducing total
T cells vs. that of other’s work specifically eliminating
IL-7Rαhigh CD4+ T cells may be due to the different
model systems. In our models, Hb is driving chronic in-
flammation by both adaptive and innate cells, whereas
the adoptive transfer models are skewed towards pro-
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Anti-IL-7R M595/50 Hb
Figure 8 Circulating mediators involved in colon inflammation and damage were reduced in H. bilis-infected Rag2−/− mice treated with
anti-IL-7Rα M595. Serum was collected at necropsy and protein expression determined using the RodentMAP version 2.0 antigen panel. ANOVA
followed by Dunnett’s post-test for all groups vs. isotype Hb. *p < 0.05, **p < 0.001, ***p <0.0001.
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Mdr1a−/− mice, we saw a greater decrease in total CD4+
vs. CD8+ T cells, as well as in naïve vs. activated/mem-
ory CD4+ and CD8+ T cells. Naïve T cells express high
levels of IL-7Rα, whereas activated T cells down regulate
IL-7Rα [17]. Our FACS analysis did not distinguish be-
tween activated effector cells and memory cells, but this
total population was less affected by IL-7Rα blockade
than naïve T cells, perhaps due to lower expression of
IL-7Rα. Reducing the pool of naïve T-cells may help
control colitis by removing cells that would become acti-
vated or develop into memory cells following exposure
to Hb. Regardless of whether anti-IL-7Rα efficacy is due
to specifically decreasing IL-7Rαhigh or IL-7Rα+ T cells
in general, the combined effect of reducing both naïve
and activated/memory T cells was associated with
reduced colitis in Mdr1a−/− mice.
In Hb-infected Mdr1a−/− mice, the lower dose of anti-
IL-7Rα M595 (50 μg) was as effective in preventing col-
itis as the higher dose (500 μg), despite the lower dose
having less of an effect on reducing T-cell numbers (in
MLN). In fact, the lower dose preserved ratios of CD4+
to CD8+ and naïve to memory CD4+ cells in MLN simi-
lar to control levels. In the colon however, the reduction
in CD4 mRNA expression was the same with both doses
of M595. The lower dose of M595 was also effective in
reducing inflammatory mediators as measured in colon
and serum, indicating that a relatively low dose of M595
can also inhibit the function of T cells (and likely non-T
cells). The mechanism by which M595 antibodydecreases cellularity is likely due more to population
decay by inhibiting survival signals [18,19] rather than
direct depletion of target cells. However, antibody-
dependent cell-mediated cytotoxicity (ADCC) measure-
ments of M595 showed it to be weakly lytic (Amgen
Inc.; data not shown). It would be interesting to perform
these colitis studies with a re-engineered anti-IL-7Rα
antibody that does not have the confounding variable of
ADCC. Further dose–response studies would be needed,
but these results suggest there may be a therapeutic win-
dow for anti-IL-7Rα in inflammatory disease settings
whereby T-cell function would be controlled without
significant lymphopenia.
Given the significant alterations of chemokines and
cytokines associated with innate immune cells in the
serum and colon in the Mdr1a−/− model, we explored
anti-IL-7Rα treatment in a Rag2−/− model of colitis.
Amelioration of disease with anti-IL-7Rα treatment in
the Rag2−/− colitis model suggested that IL-7Rα expres-
sing non-T cells, including macrophages, DCs, and NK
cells are important in bacterial-induced disease. In fact,
there were moderate (but significant) increases in sur-
face expression of IL-7Rα on splenic macrophage and
DC populations in Hb-infected-Rag2−/− mice. Multiple
myeloid cell populations, along with inflammatory cyto-
kines and chemokines associated with their function,
were decreased with anti-IL-7Rα antibody treatment in
Hb-infected Rag2−/− mice. Our findings differ from the
conclusions reported by Shinohara and colleagues in
which they used an adoptive transfer model of colitis to
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on other cells (NK cells, granulocytes, macrophages, and
DC), was essential for development of colitis [20]. How-
ever, the adoptive transfer model of colitis is dependent
on IL-7R-mediated expansion of T cells for induction of
colitis, in contrast to our models wherein bacterial anti-
gens drive inflammation and colitis involving resident
host T cells (when present) and other innate immune
cells. It is possible that IL-7R expression by cells other
than CD4+ T cells has a modest effect in their model as
they noted a trend of increased colitis scores in IL-7R−/−
x Rag2−/− recipients of wildtype naïve T cells compared
to Rag2−/− -only recipients, although these differences
were not significant [20].
Our studies using Mdr1a−/− and Rag2−/− mice strongly
suggest that cells other than CD4+ T cells are important
in bacterial-induced colitis. DCs along with other APCs,
are likely involved in the development of colitis [21]. In
Hb-infected Rag2−/− mice, we found that both pDCs and
mDCs were significantly increased with colitis and dra-
matically decreased with anti-IL-7Rα treatment, espe-
cially IL-7Rα+ pDCs. In Mdr1a−/− mice, DC-derived
cytokines and DC-activation markers CD80 and CD86
were increased with disease and significantly decreased
with anti-IL-7Rα antibody treatment. These results are
highly consistent with other studies in T-cell sufficient
mice, where IL-7 production from DCs and/or IL-7R
signaling in DCs may regulate the proliferation and acti-
vation status of CD4+ T cells [22] involved in colitis.
Our results showed that NK cells may be associated
with Hb-induced colitis. We found that lymphotactin,
produced by and chemotactic for NK cells, was
increased with disease and decreased following anti-IL-
7Rα M595 treatment in both Rag2−/− and Mdr1a−/−
mice infected with Hb. A regulatory role for NK cells
was demonstrated in one adoptive transfer model of IBD
[23], whereas another study showed NK cells neither
suppressed nor exacerbated adoptive transfer-induced
IBD [24]. Our findings using Rag2−/− mice infected with
Hb indicated that total NK and IL-7Rα+ NK cells were
associated with promoting IBD rather than suppression.
Further studies using various IBD models are needed to
clarify the function of NK cells in experimental colitis.
IL-7 promotes inflammation in part via activation of
monocytes and macrophages [25] and induces proin-
flammatory cytokines and chemokines. In our two mod-
els, blockade of IL-7Rα decreased colonic F4/80+ cells
and CD68 mRNA in Hb-infected Mdr1a−/− mice,
decreased subpopulations of macrophages in Hb-
infected Rag2−/− mice, and reduced monocyte-derived
chemokines in both Hb-infected Mdr1a−/− and Rag2−/−
mice. Shinohara and colleagues report that only IL-7R+
CD4+ T cells (and not NK cells, granulocytes, DCs, or
macrophages) contribute to colitis in their adoptivetransfer model [20], whereas von Freeden-Jeffry and col-
leagues reported that in the absence of T and B cells, IL-
7 dramatically increases F4/80+ cell infiltration into the
intestinal mucosa upon H. hepaticus infection resulting
in chronic intestinal inflammation [8]. The main differ-
ence between these studies is the use of adoptive trans-
fer of T cells into a lymphopenic environment vs. use of
a bacterium to trigger IBD. Whereas T cells are import-
ant for IBD pathogenesis, our conclusions that non-T
cells are also important in intestinal inflammation is
aligned with von Freeden-Jeffry’s results. Our results
using pharmacological blockade of IL-7Rα in T-cell suf-
ficient and T- and B-cell-deficient mice clearly establish
the contributions of both T cells and non-T cells such as
macrophages, DCs and NK cells in IBD pathogenesis.Conclusions
In summary, our studies are consistent with other mod-
els of gastrointestinal inflammation in which anti-IL-
7Rα antibody therapy ameliorated IBD [10,15,26]. How-
ever, we further show using a bacterial trigger of colitis
in a T-cell competent model and a non-T non-B cell
model, that blocking IL-7Rα can decrease inflammatory
responses via its effect on multiple immune cells that
include not only T cells, but also B cells, macrophages,
DC, and NK cells. Importantly, complete depletion of
T-cells (or myeloid cells) was not required to success-
fully treat colitis. Our studies demonstrate an important
function of IL-7R-driven immunity in experimental col-
itis and indicate that the therapeutic efficacy of IL-7Rα
blockade involves affecting both adaptive and innate
immunity.Additional files
Additional file 1: Figure S1. Naïve and activated/memory T cells were
reduced in MLN in H. bilis-infected Mdr1a−/− mice treated with anti-IL-
7Rα M595. MLN were harvested from mice shown in Figure 1a and cells
were stained with antibodies to identify T-cell subsets by flow cytometry.
Cell numbers of MLN (A) naïve (CD44-CD62Lhi), (B) activated/memory
(CD44+CD62Llow) CD4+ T cells, (C) naïve (CD44-), and (D) activated/
memory (CD44+) CD8+ T cells are shown. Significant differences are
shown (ANOVA followed by Tukey’s post-test or multivariate t method.
*p < 0.05, **p < 0.001, ***p <0.0001).
Additional file 2: Figure S2. Circulating concentrations of
H. bilis-specific antibodies were lower in infected Mdr1a−/− mice treated
with anti-IL-7Rα M595. Serum was collected from mice shown in
Figure 1a and analyzed for Hb-specific IgG2a by ELISA. Anti-Hb
absorbance was determined by calculating the average absorbance of
each sample minus the average absorbance of the control wells. Data
represent the mean ± SEM for each treatment group at each dilution. For
statistical calculations, the optical density of each sample was multiplied
by the dilution factor, then the values obtained in the 500-, 5000-, and
50,000-fold dilution groups were summed. The two anti-IL-7Rα M595-
treated groups were compared to the isotype control group by taking
the rank transformation of the data and performing ANOVA with
Dunnett’s post-test. *p < 0.05, **p < 0.01.
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http://www.journal-inflammation.com/content/9/1/39Additional file 3: Table S1. Expression of serum and colon explant
proteins and colon mRNA that were altered with colitis and with anti-IL-
7Rα M595 antibody treatment in Hb-infected Mdr1a-/- mice.
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